Florida is currently home to 3774 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Miami, Tampa, Jacksonville and Orlando. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Phase 1/2 Study of REGN5458 in Adult Patients With Relapsed or Refractory Multiple Myeloma
Recruiting
The main purpose of this study is to learn about the safety of REGN5458 and to find out what is the best dose of REGN5458 to give to patients with multiple myeloma. An additional purpose is to look for any signs that REGN5458 can treat cancer. The study is looking at several other research questions, including: * Side effects that may be experienced by people receiving REGN5458 * How REGN5458 works in the body * How much REGN5458 is present in the blood * How REGN5458 may work to treat cancer
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/14/2025
Locations: Sylvester Comprehensive Cancer Center, Miami, Florida
Conditions: Multiple Myeloma
Investigation of Rifampin to Reduce Pedal Amputations for Osteomyelitis in Diabetics
Recruiting
The purpose of this research study is to determine if rifampin, an antibiotic (a medicine that treats infections), is effective in treating osteomyelitis (infection of the bone) of the foot in diabetic patients. Despite use of powerful antibiotics prescribed over a long period of time, many diabetic patients remain at a high risk for needing an amputation of part of the foot or lower leg because the osteomyelitis is not cured. Some small research studies have shown that addition of rifampin to o... Read More
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
05/14/2025
Locations: Bay Pines VA Healthcare System, Pay Pines, FL, Bay Pines, Florida
Conditions: Osteomyelitis, Diabetes, Amputation
BBD Longitudinal Study of Osteogenesis Imperfecta
Recruiting
Osteogenesis Imperfecta (OI) is a rare disorder of increased bone fragility characterized by fractures with minimal or absent trauma, dentinogenesis imperfecta (DI), and, in adult years, hearing loss. It is seen in both genders and all races. The clinical features of OI represent a continuum varying from perinatal lethality to individuals with severe skeletal deformities, mobility impairments, and very short stature to nearly asymptomatic individuals with a mild predisposition to fractures, norm... Read More
Gender:
ALL
Ages:
All
Trial Updated:
05/14/2025
Locations: University of South Florida, Tampa, Florida
Conditions: Osteogenesis Imperfecta
Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma
Recruiting
The purpose of the study is to evaluate the effect of Elranatamab therapy after cilta-cel measuring how long a patient with high risk relapsed myeloma lives without the myeloma getting worse(progressing), also known as progression-free survival (PFS). Patients with clinical high-risk myeloma, defined as having history of myeloma that has grown outside of the bones or having high risk mutations in the myeloma cells, benefit less from cilta-cel compared to myeloma patients without these characteri... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Myeloma
A Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of TERN-601 in Adults With Overweight or Obesity
Recruiting
This is a Phase 2a multicenter, randomized, double-blind, placebo-controlled clinical trial studying the efficacy, safety, and tolerability of orally administered TERN-601 in adults with overweight or obesity.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/13/2025
Locations: FALCON Research Site, Port Orange, Florida
Conditions: Overweight or Obesity
Safety and Immunogenicity Study of Revaccination With SCB-1019T in Healthy Adults
Recruiting
CLO-SCB-1019-002 is the first study of SCB-1019T vaccine for revaccination in older adults who were previously vaccinated with AREXVY. The safety, tolerability and immunogenicity of SCB-1019T are assessed.
Gender:
ALL
Ages:
Between 60 years and 85 years
Trial Updated:
05/13/2025
Locations: AMR Fort Myers, Fort Myers, Florida
Conditions: RSV Infection
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
Recruiting
This is a Phase I/II, multi-site, open-label, two-part study designed to evaluate the efficacy, safety, optimized dose and contribution of components of BNT323 in combination with BNT327 in participants with hormone receptor-positive (HR+) or hormone receptor-negative (HR-), Human epidermal growth factor receptor (HER)2-low (immunohistochemistry \[IHC\] 1+ or IHC 2+/in situ hybridization -), HER2-ultralow (IHC 0, with membrane staining), or HER2-null breast cancer (BC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2025
Locations: Hematology - Oncology Associates of the Treasure Coast, Port Saint Lucie, Florida
Conditions: Advanced Breast Cancer, Metastatic Breast Cancer
Study of OP-3136 in Advanced or Metastatic Solid Tumors
Recruiting
This is a first-in-human, open-label, multicenter phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of OP-3136, a lysine acetyltransferases 6A and 6B (KAT6A/B) inhibitor, in participants with advanced solid tumors. This study consists of 2 parts: a dose escalation part (Part 1) and dose expansion part (Part 2).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2025
Locations: Florida Cancer Specialists, Sarasota, Florida
Conditions: Advanced or Metastatic ER+ HER2- Breast Cancer (mBC), Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC), Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC)
A Study to Investigate the Safety and Efficacy of TMP-301 Compared to Placebo in Adult Patients With Alcohol Use Disorder
Recruiting
TMP-301 has been shown in preclinical models to reduce consumption of alcohol and other addictive substances. It has been tested in healthy subjects and has been found to be safe and tolerated at doses predicted to be efficacious in alcohol use disorder. This study is being conducted to evaluate the safety, tolerability and efficacy of TMP-301 in patients with alcohol use disorder.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/13/2025
Locations: Research Centers of America, LLC, Hollywood, Florida
Conditions: Alcohol Use Disorder (AUD)
Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Moderatetosevere Asthma.
Recruiting
This is a phase 2, open-label extension study to evaluate the long-term safety and efficacy of lunsekimig in adult participants with moderate-to-severe asthma who have previously completed the parent study. After completion of the parent study, eligible participants will be offered the opportunity to participate in the long-term extension (LTE) study with lunsekimig. The study duration will be up to 100 weeks with a treatment duration being up to 96 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2025
Locations: Qway Research - Hialeah- Site Number : 8400015, Hialeah, Florida
Conditions: Asthma
A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.
Recruiting
The ASPIRE trial is a 52 week randomized, double-blind, placebo-controlled, parallel-group, multicenter trial in which the efficacy, safety, and pharmacokinetics of orally administered buloxibutid, either on top of stable IPF therapy or as monotherapy, are assessed in participants with IPF. Trial website: www.aspire-ipf.com
Gender:
ALL
Ages:
40 years and above
Trial Updated:
05/13/2025
Locations: University of Florida Health (UF Health), Gainesville, Florida
Conditions: Idiopathic Pulmonary Fibrosis (IPF)
A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis
Recruiting
The main objective of the study will be to evaluate the efficacy of rocatinlimab compared with placebo at week 24 on the patient-reported outcome (PRO) measure of pruritus and overall clinical assessment score (US only).
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
05/13/2025
Locations: Direct Helpers Research Center, Hialeah, Florida
Conditions: Prurigo Nodularis